

Metabolomic analysis of alterations in lipid oxidation, carbohydrate and amino acid metabolism in dairy goats caused by exposure to Aflatoxin B1

Jianbo Cheng^{1,2†}, Shuai Huang^{1†}, Caiyun Fan¹, Nan Zheng^{2,3}, Yangdong Zhang^{2,3}, Songli Li^{2,3} and Jiaqi Wang^{2,3*}

¹ College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, People's Republic of China

² State Key Laboratory of Animal Nutrition, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, People's Republic of China

³ Ministry of Agriculture-Milk Risk Assessment Laboratory, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, People's Republic of China

Received 20 February 2017; accepted for publication 9 October 2017

The purposes of this study were to investigate the systemic and characteristic metabolites in the serum of dairy goats induced by aflatoxin B1 (AFB1) exposure and to further understand the endogenous metabolic alterations induced by it. A nuclear magnetic resonance (NMR)-based metabolomic approach was used to analyse the metabolic alterations in dairy goats that were induced by low doses of AFB1 (50 µg/kg DM). We found that AFB1 exposure caused significant elevations of glucose, citrate, acetate, acetoacetate, betaine, and glycine yet caused reductions of lactate, ketone bodies (acetate, β-hydroxybutyrate), amino acids (citrulline, leucine/isoleucine, valine, creatine) and cell membrane structures (choline, lipoprotein, N-acetyl glycoproteins) in the serum. These data indicated that AFB1 caused endogenous metabolic changes in various metabolic pathways, including cell membrane-associated metabolism, the tricarboxylic acid cycle, glycolysis, lipids, and amino acid metabolism. These findings provide both a comprehensive insight into the metabolic aspects of AFB1-induced adverse effects on dairy goats and a method for monitoring dairy animals exposed to low doses of AFB1.

Keywords: Aflatoxin B1, metabolic, NMR, dairy goats.

Aflatoxin B1 (AFB1), which is a mycotoxin produced mainly by *Aspergillus flavus* and *Aspergillus parasiticus*, occurs naturally in human foods and animal feeds (Zhou et al. 2006). Acute or chronic aflatoxicosis, hepatotoxicity, teratogenicity, and immunotoxicity in humans and animals as a consequence of AFB1 exposure has been reported by many researchers (Sabbioni & Sepai, 1998; Smela et al. 2001). It has been well documented that AFB1 reduces performance, alters blood profiles, decreases immune function, and influences antioxidant status as well as liver function in animals (Bennett & Klich, 2003). For this reason, AFB1 is classified as a group 1 carcinogen in humans by the International Agency for Research on Cancer (IARC), which is part of the World Health Organization (IARC, 2002). In mammals, AFB1 is metabolised to AFM1, which also has carcinogenic potency

(Creppy, 2002) and can appear in milk. Therefore, AFM1 has been classified as a probable human carcinogen (IARC, 2002). The European Commission has established the maximum admissible levels of AFB1 as 20 µg/kg in dairy animal feeds, and the allowable level of AFM1 in milk and milk products should not exceed 50 ng/kg (Commission, 2006). In China, AFB1 and AFM1 are also regulated by the Standardisation Administration of China at 20 µg/kg (SAC, 2001) and 50 ng/kg (SAC, 2003), respectively.

It is widely known that AFB1 is biotransformed by the hepatic microsomal cytochrome P450 in the liver into reactive AFB1-epoxide (AFBO). AFBO binds strongly to proteins and imparts its effect, which alters the normal biochemical functions of protein macromolecules, which can lead to deleterious effects at the cellular level (Mishra & Das, 2003). AFBO binds strongly to DNA and RNA as well, causing aflatoxins to impart their effect by means of interfering with DNA replication and transcription of messenger RNA into protein at the molecular level. Mutation is

†These authors contributed equally to this work.

*For correspondence; e-mail: jiaqi wang@vip.163.com

caused by binding of the aflatoxin molecule to DNA and subsequent erroneous protein synthesis (Bedard & Massey, 2006). Therefore, AFB1 is a biosynthetic inhibitor both *in vivo* and *in vitro*, which not only affects different metabolic pathways, such as glycogenolysis/glycolysis (Kiessling & Adam, 1986) and phospholipidation (Hsieh et al. 1988), but also changes amino acid transportation (McLean & Dutton, 1995). Smith & Moss (1985) reported that aflatoxin reduces the hepatic glycogen level. AFB1 produced various alterations in total lipid and cholesterol as well as the fatty acid composition of hepatic phosphatidylcholine and phosphatidylethanolamine in rats three weeks post-exposure (Baldwin & Parker, 1986).

Metabonomics is a powerful approach to delineating the global metabolic profiling of living organisms and capturing the subtle metabolic alterations associated with physiological and pathological stimulations. ^1H Nuclear magnetic resonance (NMR)-based metabonomics, with its simplicity of sample preparation and robust reproducibility, has been extensively used in metabonomic analysis of biofluids and tissues to study metabolic changes. The study of the endogenous metabolic alterations induced by heavy metals was used in NMR-based metabonomics, with results showing that the changes in lipid fraction, unsaturated lipids, and in the level of amino acids suggest perturbation of the metabolism of lipids and amino acids (Dudka et al. 2014). Sundekilde & Poulsen (2013) identified the biomarkers of somatic cell counts by NMR-based metabonomics including lactate, acetate, isoleucine, hippurate, butyrate, and fumarate. NMR-based metabonomics has also been applied to the toxicology investigation of the T-2 toxin (Wan et al. 2016), ochratoxin A (Sieber et al. 2009), deoxynivalenol (Hopton et al. 2010), and streptozotocin (Diao et al. 2014).

For the abovementioned reasons, we conducted this study to analyse the metabolic alterations caused by AFB1 in dairy goat serum using NMR-based metabonomics approaches. The objectives of this study were to investigate the endogenous metabolic changes induced by AFB1 exposure and to further our understanding of AFB1 toxicity at the systemic level.

Materials and methods

Animals and sample collection

All animals involved in this study were cared for according to the principles of the Chinese Academy of Agricultural Sciences Animal Care and Use Committee. Twenty lactating Laoshan dairy goats (193 ± 14 d in milk, 1.36 ± 0.4 kg of milk/d, and 3.4 ± 1.0 parity) were grouped by parity (primiparous or multiparous), average daily milk yield, and day in milk and randomly assigned to one of two treatments ($n = 10$), according to a randomized block design. The treatments were 0 (control) and $50 \mu\text{g}/\text{kg}$ AFB1 (AFB1). The AFB1 was purchased from Sigma-Aldrich (St. Louis, MO, USA) and had a purity of 98%. The experimental period consisted

of one week for adaptation to the environment followed by two weeks for the feeding of mycotoxins. The goats were assigned to a free stall barn with access to fresh water, and they were fed the total mixed ration (TMR). Pure AFB1 was separately dissolved in methanol. Pelleted concentrate was used as the mycotoxin carrier, and it was top-dressed in equal portions on the TMR at the 5:30 a.m. feeding.

Blood samples were collected from each goat before the morning feeding *via* jugular venipuncture on 14 d. Nine millilitres of blood were collected in vacuum tubes without anticoagulant, centrifuged at $3000 \times g$ for 15 min at 4°C to obtain serum, and stored at -80°C for later analysis.

Sample preparation and ^1H NMR spectroscopy

Serum samples were prepared by mixing 300 μl of serum with 100 μl of D_2O and 200 μl of phosphate buffer saline solution ($\text{K}_2\text{HPO}_4/\text{NaH}_2\text{PO}_4$, pH 7.4). After vortexing and centrifugation at 13 000 rpm for 10 min, the supernatant was pipetted into 5 mm NMR tubes for NMR analysis.

A water-presaturated Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence (recycle delay- 90° -(τ - 180° - τ) $_n$ -acquisition, where $\tau = 400 \mu\text{s}$ and $n = 400$) was employed to retain NMR signals from small metabolites and to attenuate NMR signals from macromolecules with spin-spin relaxation delays ($2n\tau$) of 320 ms. CPMG spectra with a 2 ms sample time and a 3 s relaxation delay between successive scans (64 scans per spectrum, 32 K data points, spectral width 8000 Hz) were recorded using a Varian INOVA-600 spectrometer with a pulsed field gradient and three resonance probes.

Metabolites were identified by inserting the experimental spectra into the Chenomx spectral database (Edmonton, AB, Canada) for comparison with the spectra of standard compounds.

NMR spectrum processing and multivariate data analysis

After manual corrections of both the phase and baseline, the chemical shifts were referenced internally to TSP (at $\delta = 0.0$ ppm). The chemical shift region from 0.4 to 6.0 was segmented and integrated with equal widths of 0.01 ppm. All spectral segments were normalised to the total spectral area in Excel for multivariate data analysis.

Multivariate data analysis was carried out with SIMCAP+ software (version 13.0, Umetrics, Sweden). Prior to multivariate analysis, centre scaling was applied to ^1H NMR data to reduce noise and artifacts in the models. Principal Component Analysis (PCA) was initially carried out on the NMR data to generate an overview. Partial least squares discriminant analysis (PLS-DA) models were applied to validate the model against overfitting through 999 random permutation tests. Discriminating variables were selected according to the loading plots, jack-knifed-based confidence intervals, variable importance in projection values ($\text{VIP} > 1$), and raw data plots in the orthogonal partial least squares discriminate analysis (OPLS-DA) models (Tian et al. 2015). Furthermore, independent t-tests ($P < 0.05$)




Fig. 1. (a) Score plot for the PCA model of the control and AFB1 groups. (b) Loading plots of centre-scaled ^1H NMR data in unsupervised PCA model. (c) Score plot for the OPLS-DA model of control and AFB1 groups. (d) Loading plots of centre-scaled ^1H NMR data in supervised OPLS-DA.

(SPSS version 13.0) were used to determine if the differences between the concentrations of candidate biomarkers obtained from OPLS-DA of both the control and AFB1 groups were statistically significant.

Results

Comparison of the metabolic profiles of the control and AFB1 groups

PCA models with good cluster of both the control and AFB1 groups and no strong outliers were observed (Fig. 1a). This presented apparent groupings, with only partial overlapping between the control and AFB1 data. The loading plots (Fig. 1b) reflected changes of some endogenous metabolites. To obtain improved model transparency and interpretability, OPLS-DA's for chemometric analysis were further performed to screen for differential variables. These showed a clear separation between the control and AFB1 groups without any overlap (Fig. 1c), which produced one predictive component and two orthogonal components with satisfactory modelling and predictive abilities $R^2(X) = 41.9\%$, $R^2(Y) = 91.3\%$, and $Q^2(\text{cum}) = 76.9\%$. Loading plots in Fig. 1d showed changes of significantly altered endogenous metabolites. To avoid model overfitting, a default of seven rounds of cross-validation across three components was performed. Validation with 999 random permutation tests produced intercepts of $R^2(Y) = 0.396$ and $Q^2 = -0.244$ for the data (Supplementary Fig. S1). Overall, the results indicated that the predictive capabilities of the OPLS-DA models of the NMR data were reliable.

Identification of metabolite candidates

^1H NMR analyses identified a total of 17 metabolic candidates (Table 1), which were classified into carbohydrate,

amino acid, and lipid metabolites, suggesting that these metabolic pathways were altered in the AFB1 group. Supplementary Fig. S2 shows the signal ^1H assignment of identified candidate metabolites.

Metabolic alterations

Table 1 lists the metabolic alterations between the control and AFB1 groups. AFB1-induced alterations in carbohydrate-related metabolites were observed for lactate, glucose, citrate, and acetate. The concentrations of lactate and acetate were decreased by 0.71- to 0.89-fold in the AFB1 group compared with the control group ($P < 0.01$). The concentrations of glucose and citrate were increased by 1.21- to 2.89-fold in the AFB1 group compared with the control group ($P < 0.01$). Citrulline, leucine/isoleucine, valine, glycine, creatine, and betaine are metabolites related to amino acids; the former three were decreased by 0.84- to 0.91-fold in the AFB1 group compared with the control group ($P < 0.05$), and the latter three were increased by 1.32- to 1.64-fold ($P < 0.01$). The concentrations of acetone, acetoacetate, β -hydroxybutyrate, choline, phosphatidylcholine (PC)/ glycerophosphoryl choline (GPC), lipoprotein, and N-acetyl glycoproteins are lipid-related metabolites; the former two were increased by 1.27- to 1.51-fold in the AFB1 group compared with the control group ($P < 0.01$), and the latter two were decreased by 0.77- to 0.84-fold in the AFB1 group compared with the control group ($P < 0.05$).

Discussion

AFB1's influence on liver damage

Choline, PC, and GPC are essential elements for structural integrity of cell membranes. The significant decreases in

Table 1. Candidate metabolite identified by ^1H NMR

No.	Metabolic pathway	Metabolite	Chemical shift (ppm)	Assignment [†]	P^{\ddagger}	FC [§]
1	Carbohydrate	Lactate	1.33	CH ₃ (d)	4.48×10^{-4}	0.71
2	Carbohydrate	Glucose	5.25(d), 4.66(d)	CH ₂ (d)	6.47×10^{-3}	1.21
3	Carbohydrate	Citrate	2.54, 2.67	2 × CH ₂ (d)	1.62×10^{-5}	2.89
4	Carbohydrate	Acetate	1.91	CH ₃ (s)	7.75×10^{-3}	0.89
5	Amino acid	Citrulline	3.71	CH (m)	2.62×10^{-2}	0.91
6	Amino acid	Leucine/Isoleucine	0.92–0.97	CH ₃ (d)	8.53×10^{-3}	0.87
7	Amino acid	Valine	0.98, 1.03	2 × CH ₃ (d)	3.45×10^{-2}	0.84
8	Amino acid	Glycine	3.57	CH ₂ (s)	2.64×10^{-3}	1.32
9	Amino acid	Creatine	3.05, 3.94	CH ₂ (s)	3.84×10^{-5}	1.40
10	Amino acid	Betaine	3.26	3 × CH ₃ (s)	3.39×10^{-3}	1.64
11	Lipid	Acetone	2.24	2 × CH ₃ (s)	2.25×10^{-3}	1.51
12	Lipid	Acetoacetate	2.29	CH ₃ (s)	6.58×10^{-4}	1.27
13	Lipid	β -hydroxybutyrate	1.19	CH ₃ (s)	9.38×10^{-3}	0.80
14	Lipid	Choline	3.20	3 × CH ₃ (s)	3.03×10^{-2}	0.77
15	Lipid	PC/GPC	3.23	3 × CH ₃ (s)	1.62×10^{-2}	0.87
16	Lipid	Lipoprotein	0.82–0.88	CH ₃ (t)	2.68×10^{-2}	0.78
17	Lipid	Nacetyl glycoproteins	2.03	CH ₃ (s)	2.49×10^{-2}	0.83

[†](d) doublet, (s) singlet, (dd) double doublet, (m) multiplet, (t) triplet

[‡] P , independent t -test for control vs. AFB1

[§]FC, fold change in the metabolite concentration (AFB1/control)

serum levels of choline, PC, and GPC in AFB1 treated goats indicated that AFB1 causes liver damage, which was in line with the decrease of lipoprotein and N-acetyl glycoproteins in the serum. As an organic osmolyte, betaine can be excreted into serum to maintain osmolarity and protect against cell damage in hypotonic conditions when hepatocytes swell and lead to the accumulation of intracytoplasmic fluids in cells (Zerbst-Boroffka et al. 2005). The observation of elevated levels of betaine in the current study suggested that both the swelling of hepatocytes and subsequent liver damage had occurred.

Previous evidence from gene expression also supports these results. Several genes that were encoding cytoskeletal organisation were up-regulated in both middle- (0.75 mg/kg body weight) and high-dose (1.5 mg/kg body weight) AFB1 groups of rats, including Rhob in both groups and Anxa1, Anxa2, Anxa4, Anxa5, Anxa7, and Arpc1b in the high-dose group (Lu et al. 2013). Additional supportive evidence of liver damage induced by AFB1 was found in rats that were dosed with 0.24 mg/(kg/day) of AFB1 for 14 d, where genes encoding the cytoskeletal constituent were up-regulated, including CRYAB α B-crystallin, RhoB, SPTA2 spectrin α chain (fodrin α chain), and TMSB 10 thymosin β -10 (Ellinger-Ziegelbauer et al. 2004).

AFB1's impact on carbohydrate metabolism

An increase in citrate excretion together with decreased lactate excretion was observed with ^1H NMR detection, which suggested impairments in both Cori and Krebs cycle metabolism in periods of altered energy production, which may be linked to damaged mitochondrial function. The major function of electron transport is ATP synthesis in mitochondrion. The depletion of ATP that was seen

resulted from impaired energy metabolism. A previous investigation also reported that ATP synthesis pathways are more affected in chicks fed 2 mg of AFB1/kg, leading to decreased energy production and the genes being down-regulated, such as in the adrenodoxin mitochondrial precursor, cytochrome P450 2C5, cytochrome P450 2P3, and nicotinamide adenine dinucleotide phosphate-cytochrome b5 reductase (Yarru et al. 2009). Consistent with the findings in broilers (Tessari et al. 2010) and ducks (He et al. 2013), our goats that were fed diet supplements of 50 $\mu\text{g}/\text{kg}$ of AFB1 had a 1.21-fold changes of the glucose level in serum, indicating that liver function had been damaged and that a consequence of AFB1 exposure is an accelerated rate of glycogenolysis. Such depletion of hepatic glucose has also been observed in rats dosed with 0.32 mg/(kg body weight/day) of AFB1 (Zhang et al. 2011).

AFB1's impacts on lipid metabolisms

A previous investigation found increases in the relative liver weights of chicks that were fed aflatoxin (Ortatatli & Oğuz, 2001). In this study, we observed decreased levels of β -hydroxybutyrate and acetate in the serum after AFB1 treatments, indicating that AFB1 exposure alters the lipid metabolism of goats. These results were consistent with the findings of Yarru et al. (2009), who found that genes involved in fatty acid metabolism were downregulated in chicks that were fed 2 mg/kg of AFB1. Acetoacetate and acetone are the products of the β -oxidation of fatty acid in mitochondria, hence, their elevations in this study suggested the promotion of β -oxidation of fatty acid with AFB1 exposure. In agreement with our findings, a previous investigation found that AFB1 exposure caused up-regulation of

peroxisome proliferator-activated receptor R, a key regulator of lipid metabolism (Yarru et al. 2009).

AFB1's impact on amino acid metabolism

In this study, AFB1 induced an increase in the levels of citrulline, leucine/isoleucine, and valine and a decrease in the level of glycine, which implies that AFB1 altered hepatic amino acid metabolism. Moreover, a noticeable increase in creatine levels was observed in the serum of AFB1-treated goats. Phosphocreatine, an energy reservoir, can be rapidly converted to creatine by creatine kinase and the release of adenosine triphosphate (ATP) and creatine in response to high energy demands (Diao et al. 2014). Suppression of the tricarboxylic acid (TCA) cycle caused by AFB1 exposure will inevitably result in insufficient energy production. Hence, the accumulated creatine in the serum of AFB1 exposed goats may be the result of the accelerated conversion of phosphocreatine to creatine to meet this energy demand. The decreased serum levels of citrulline implied that the urea cycle was interrupted by AFB1 because it is the intermediate metabolite in the urea cycle. This is inconsistent with the AFB1-induced down-regulation of gene expression of carbamoyl-phosphate synthetase I in mice (Zhuang et al. 2014).

Conclusion

In conclusion, dairy goats' exposure to low doses of AFB1 caused significant alterations in several metabolic pathways, including lipid oxidation, TCA cycle, and carbohydrate and amino acid metabolism. Our results also show that ¹H NMR-based metabolomic analysis of the serum provided an effective method for understanding AFB1's adverse effects on goats' health at low levels as well as a method for preventing AFM1 contamination of milk.

Supplementary material

The supplementary material for this article can be found at <https://doi.org/10.1017/S0022029917000590>.

This work was supported financially by Agro-scientific Research in the Public Interest (201403071), Introduction of International Advanced Agricultural Science and Technology Program (2015-Z12; 2016-X37) and The Agricultural Science and Technology Innovation Program (ASTIP-IAS12).

References

- Baldwin S & Parker RS** 1986 Effects of dietary fat level and aflatoxin B1 treatment on rat hepatic lipid composition. *Food and Chemical Toxicology* **23** 1049–1055
- Bedard LL & Massey TE** 2006 Aflatoxin B1-induced DNA damage and its repair. *Cancer Letters* **241** 174–183
- Bennett JW & Klich M** 2003 Mycotoxins. *Clinical Microbiology Reviews* **16** 497–516

- Commission E** 2006 Commission regulation (EC) No 1881/2006 of 19 December 2006, setting maximum levels for certain contaminants in foodstuff, pp. 5–24. Official Journal of the European Union
- Creppy EE** 2002 Update of survey, regulation and toxic effects of mycotoxins in Europe. *Toxicology Letters* **127** 19–28
- Diao C, Zhao L, Guan M, Zheng Y, Chen M, Yang Y, Lin L, Chen W & Gao H** 2014 Systemic and characteristic metabolites in the serum of streptozotocin-induced diabetic rats at different stages as revealed by a (1)H-NMR based metabolomic approach. *Molecular Biosystems* **10** 686–693
- Dudka I, Kossowska B, Senhadri H, Latajka R, Hajek J, Andrzejak R, Antonowicz-Juchniewicz J & Gancarz R** 2014 Metabonomic analysis of serum of workers occupationally exposed to arsenic, cadmium and lead for biomarker research: a preliminary study. *Environment International* **68** 71–81
- Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W & Ahr HJ** 2004 Characteristic expression profiles induced by genotoxic carcinogens in rat liver. *Toxicological Sciences* **77** 19–34
- He J, Zhang KY, Chen DW, Ding XM, Feng GD & Ao X** 2013 Effects of maize naturally contaminated with aflatoxin B1 on growth performance, blood profiles and hepatic histopathology in ducks. *Livestock Science* **152** 192–199
- Hopton RP, Turner E, Burley VJ, Turner PC & Fisher J** 2010 Urine metabolite analysis as a function of deoxynivalenol exposure: an NMR-based metabolomics investigation. *Food Additives and Contaminants* **27** 255–261
- Hsieh LL, Hsu SW, Chen DS & Santella RM** 1988 Immunological detection of aflatoxin B1-DNA adducts formed in vivo. *Cancer Research* **48** 6231–6238
- IARC (International agency for research on cancer)** 2002 Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. In *IARC Working Group on the Evaluation of Carcinogenic Risks to Humans*, pp. 1–556 Ed. World Health Organization: France
- Kiessling KH & Adam G** 1986 Biochemical mechanism of action of mycotoxins. *Pure and Applied Chemistry* **58** 327–338
- Lu XY, Hu B, Shao L, Tian Y, Jin TT, Jin YC, Ji S & Fan XH** 2013 Integrated analysis of transcriptomics and metabolomics profiles in aflatoxin B1-induced hepatotoxicity in rat. *Food and Chemical Toxicology* **55** 444–455
- Mclean M & Dutton MF** 1995 Cellular interactions and metabolism of aflatoxin: An update. *Pharmacology & Therapeutics* **65** 163–192
- Mishra HN & Das C** 2003 A review on biological control and metabolism of aflatoxin. *Critical Reviews in Food Science and Nutrition* **43** 245–264
- Ortatli M & Oğuz H** 2001 Ameliorative effects of dietary clinoptilolite on pathological changes in broiler chickens during aflatoxicosis. *Research in Veterinary Science* **71** 59–66
- Sabbioni G & Sepai O** 1998 Determination of human exposure to aflatoxins. In *Mycotoxins in Agriculture and Food Safety*, pp. 183–226 (Eds KK Sinha & D Bhatnagar). New York: Marcel Dekker, Inc., Publisher
- SAC (Standardization Administration of the People's Republic of China)** 2001 *Hygienical Standard for Feeds*, p. 20. Beijing: Standards Press of China Publisher
- SAC (Standardization Administration of the People's Republic of China)** 2003 *Maximum Levels of Aflatoxin M1 in Milk and Milk Products*, p. 1. Beijing: Standards Press of China Publisher
- Sieber M, Wagner S, Rached E, Amberg A, Mally A & Dekant W** 2009 Metabonomic study of ochratoxin a toxicity in rats after repeated administration: phenotypic anchoring enhances the ability for biomarker discovery. *Chemical Research in Toxicology* **22** 1221–1231
- Smela ME, Currier SS, Bailey EA & Essigmann JM** 2001 The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. *Carcinogenesis* **22** 535–545
- Smith JE & Moss MO** 1985 Mycotoxins. *Formation, Analysis and Significance*, p. 148. Wiley Publisher
- Sundekilde UK & Poulsen NA** 2013 Nuclear magnetic resonance metabolomics reveals strong association between milk metabolites and somatic cell count in bovine milk. *Journal of Dairy Research* **96** 290–299
- Tessari ENC, Kobashigawa E, Cardoso ALSP, Ledoux DR, Rottinghaus GE & Oliveira CAF** 2010 Effects of aflatoxin B1 and

- fumonisin B1 on blood biochemical parameters in broilers. *Toxins* **2** 453–460
- Tian H, Wang WY, Zheng N, Cheng JB, Li SL, Zhang YD & Wang JQ** 2015 Identification of diagnostic biomarkers and metabolic pathway shifts of heat-stressed lactating dairy cows. *Journal of Proteomics* **125** 17–28
- Wan QF, He QH, Deng XB, Hao FH, Tang HR & Wang YL** 2016 Systemic metabolic responses of broiler chickens and piglets to acute T-2 toxin intravenous exposure. *Journal of Agricultural and Food Chemistry* **64** 714–723
- Yarru LP, Settivari RS, Antoniou E, Ledoux DR & Rottinghaus GE** 2009 Toxicological and gene expression analysis of the impact of aflatoxin B1 on hepatic function of male broiler chicks. *Poultry Science* **88** 36–371
- Zerbst-Boroffka I, Kamalynow RM, Harjes S, Kinne-Saffran E & Gross J** 2005 TMAO and other organic osmolytes in the muscles of amphipods (crustacea) from shallow and deep water of lake baikal. *Comparative Biochemistry and Physiology A-Molecular & Integrative Physiology* **142** 58–64
- Zhang LM, Ye YF, An YP, Tian Y, Wang YL & Tang HR** 2011 Systems responses of rats to aflatoxin B1 exposure revealed with metabolomic changes in multiple biological matrices. *Journal of Proteome Research* **10** 614–623
- Zhou QB, Xie H, Zhang L, Stewart JK, Gu XX & Ryan JJ** 2006 Cis-Terpenones as an effective chemopreventive agent against aflatoxin B1-induced cytotoxicity and TCDD-induced P450 1A/B activity in HepG2 cells. *Chemical Research in Toxicology* **19** 1415–1419
- Zhuang ZH, Lin YN, Yang C, Yuan J & Wang SH** 2014 Study on CPS1: The key gene of urea cycle under the stress of aflatoxin B1. *Asian Journal of Chemistry* **26** 3305–3310